Rates of hemorrhage during warfarin therapy for atrial fibrillation. - sprookjes - yvandenbroek - TriplyDB

Rates of hemorrhage during warfarin therapy for atrial fibrillation.

Rates of hemorrhage during warfarin therapy for atrial fibrillation.

http://www.wikidata.org/entity/Q36586263

about

Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation Varenicline and Risk of Self-Harm: A Nested Case-Control Study Guideline-concordant administration of prothrombin complex concentrate and vitamin K is associated with decreased mortality in patients with severe bleeding under vitamin K antagonist treatment (EPAHK study).High resolution melting method to detect single nucleotide polymorphism of VKORC1 and CYP2C9.Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban.Evaluation of an initiation protocol of 4 mg of warfarin for atrial fibrillation in the outpatient setting.Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registry.Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies The three-year incidence of major hemorrhage among older adults initiating chronic dialysis.Risk of bleeding and stroke with oral anticoagulation and antiplatelet therapy in patients with atrial fibrillation in Taiwan: a nationwide cohort study.Clinical Benefit of American College of Chest Physicians versus European Society of Cardiology Guidelines for Stroke Prophylaxis in Atrial Fibrillation Impact of Rural Residence on Warfarin Use and Clinical Events in Patients with Non-Valvular Atrial Fibrillation: A Canadian Population Based Study.Adherence to oral anticoagulants in patients with atrial fibrillation-a population-based retrospective cohort study linking health information systems in the Valencia region, Spain: a study protocol.Natural history of bleeding and characteristics of early bleeders among warfarin initiators - a cohort study in Finland.The Influence of Socioeconomic Status on Selection of Anticoagulation for Atrial Fibrillation Assessment and comparison of CHADS2, CHA2DS2-VASc, and HAS-BLED scores in patients with atrial fibrillation in Saudi Arabia The Characteristics of Treated Pulmonary Arterial Hypertension Patients in Ontario.Current strategies to minimize the bleeding risk of warfarin.Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation New oral anticoagulants: are coagulation units still required?Warfarin and atrial fibrillation: from ideal to real the warfarin affaire.Co-Prescribing of Potentially Interacting Drugs during Warfarin Therapy - A Population-Based Register Study.Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs).Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago.Influence of APOE Gene Polymorphism on Interindividual and Interethnic Warfarin Dosage Requirement: A Systematic Review and Meta-Analysis.Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients.Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges.Management and outcome of gastrointestinal bleeding in patients taking oral anticoagulants or antiplatelet drugs.Overcoming global challenges in stroke prophylaxis in atrial fibrillation: The role of non-vitamin K antagonist oral anticoagulants.Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation.Stroke risk reduction outweighed bleeding risk increase from vitamin K antagonist treatment among nonvalvular atrial fibrillation patients with high stroke risk and low bleeding risk.The appropriateness and persistence of testosterone replacement therapy in Ontario.Generic switching of warfarin and risk of excessive anticoagulation: a Danish nationwide cohort study.The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study.Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study.Warfarin and absolute risk of hemorrhagic stroke.Hospitalization for vitamin-K-antagonist-related bleeding: treatment patterns and outcome.Tossing a coin or using common sense.

P2860

Q21284803-81B88670-8A97-485E-B056-5617EA6B0251 Q26776413-5E4E04A4-C142-4C8A-BDDB-845F64E316B1 Q28554332-967CD4D7-C476-4306-AD6E-3EF8834BCBFC Q33753659-1F488015-20C6-4A39-ABE5-DFA3C3F056B4 Q33802999-5B67D800-F6D1-4EAE-A53A-63076ABEE4AA Q34019616-6D8B5AB5-C7BB-465E-8BB7-7F65F1FD4C82 Q34260267-D610EA0A-A5EF-4E0F-9131-B52AD01805F9 Q34497645-C3F894FB-A9C8-425B-8472-30DD1A033CA4 Q34554492-DD55D3BB-861E-4DE6-A9BE-AC71E7E89D83 Q34585334-9292F593-AB80-4461-8DA2-47C08079E723 Q35147637-DB0309B0-8DE1-4612-A93D-0DCA01EE4D1C Q35553343-6619A96F-65B4-4765-A5E2-A6872A75CD7C Q35638248-16B5E07B-CE7C-4BF6-9F47-CD7A94B5A546 Q35806598-437064FB-A0C1-488B-9B3C-517BBB73455B Q36179688-408C450D-5B5B-43A5-91BB-0338AD3A3D2A Q36575256-486B29E3-FE94-4294-9257-D01BCB29C093 Q36620779-94F00A8E-F044-4E97-AEBF-83DCEEE067EB Q36861474-5D1BE9E9-191E-4EB7-9EC3-8054FF518C70 Q36996773-94772A46-C0B2-42BC-AC79-98D53405DBEF Q37140198-8FEDBE5F-4A74-4737-86DD-3EA631550D11 Q37578065-8FB2E2E1-5FD4-48F4-A1F3-32BC2ABA8979 Q37593158-75586286-EA00-40D8-9F83-B69A75B56372 Q37607493-0E184EC2-8E4B-4C26-8B3A-DD8A7A02475B Q38417110-078DF694-375F-4107-949A-5927D5E95B44 Q38458642-E4DE566B-C856-40F0-8623-D0F3EFAEC2C2 Q38787469-9D65F3AF-A98D-4749-8B42-2156F72E2A25 Q38803472-8619BF05-0C90-4A84-B9F0-581D8FDE1AB4 Q38821650-5443FDAA-8821-432F-B502-EF5EE25B8EF1 Q38851232-955829FC-F318-4F3E-BCCF-4A3E8E743F19 Q38955911-91819FBE-1237-466C-89C0-3A64FBA8AB57 Q38972270-968F1F9B-B297-4987-99B1-E48FCEEF9C5B Q39023182-7B10B0DA-8C0E-4B59-8716-1AE0745CC78B Q39069401-BD8FA125-8B0C-443C-83E8-6E8E7E56B629 Q39486784-DA92C1B2-422C-4737-9412-0B6ABCB60657 Q40179302-3C44F185-3497-43EC-BD35-A9809F1B43AC Q41486453-1ED254FE-5143-424A-B10D-00CC817841DF Q42697506-2A859453-0F4C-4126-AD00-ED212246133A Q43164482-F7D3E8D2-02FE-4B61-9388-14AE0A754F46 Q43650765-D63394C4-BDDD-4137-ADC8-A9F5F7886BD3 Q45341136-64BFB5A0-52F4-4B6F-92F4-253AE41FC38B

P2860

Rates of hemorrhage during warfarin therapy for atrial fibrillation.

http://www.wikidata.org/entity/Q36586263

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Rates of hemorrhage during warfarin therapy for atrial fibrillation.

@ast

Rates of hemorrhage during warfarin therapy for atrial fibrillation.

@en

type

label

Rates of hemorrhage during warfarin therapy for atrial fibrillation.

@ast

Rates of hemorrhage during warfarin therapy for atrial fibrillation.

@en

prefLabel

Rates of hemorrhage during warfarin therapy for atrial fibrillation.

@ast

Rates of hemorrhage during warfarin therapy for atrial fibrillation.

@en

P1433

Q36586263-B127552D-396F-428F-931F-2843453B2CE8

P1476

Q36586263-1DA39A63-6C91-4270-9746-5EA3114FA1EF

P2093

Q36586263-0C1149DF-DE50-4F94-9D2A-CAC033AFA0F8

Q36586263-378BD639-801A-4AE2-98E1-AF640495A329

Q36586263-5E367A7C-0A09-46C1-9694-FC5DAAF980BB

Q36586263-5E3EC7CD-BF0D-47C3-B023-819EA8AE13E2

Q36586263-95CC33D7-5381-412A-84C0-4C59BB281E83

Q36586263-B47669EC-9C52-49B8-8F3D-328E9916F04D

P2860

Q36586263-0B22A83B-1CC6-4372-824D-401435D57C79

Q36586263-0FBDE06C-F210-485F-9C63-DC68EA563D76

Q36586263-144CC72C-F4EB-4E88-B766-AF22975157B7

Q36586263-19694C29-B099-4CDE-957B-7707A13068F3

Q36586263-1ED1CC16-4877-40D9-A394-3F9999027371

Q36586263-263B4558-9FF2-4B4A-901F-A37333A016E0

Q36586263-28101A72-120B-4B37-9BDD-AE38F94C9EB5

Q36586263-2CCA05CE-06BE-4ADF-8D40-3525C07308E4

Q36586263-389EA38D-ADBA-4B41-81C5-FA0280A8D313

Q36586263-38F946C1-8D5E-428F-848E-9C6A52037569

P304

Q36586263-21698A41-9EE2-43C3-B337-1717D30CEE2E

P31

Q36586263-6044B6BE-DA4A-44CC-B73E-1E881C431719

P356

Q36586263-D9AA1183-B4F4-4554-ACA3-9B1A53C8E2DD

P407

Q36586263-992985C5-6D0F-427B-80AB-0BCCE9FF7951

P433

Q36586263-141D16D2-7E96-4F10-A98E-23E972CF0630

P478

Q36586263-DBE09D8A-039B-4CCF-BBC0-12F494829882

P577

Q36586263-769F19C6-BBE0-4211-895C-8E8E1AF0B081

P5875

Q36586263-7F7D11A7-67EF-484E-BB7A-6F45B6A9800C

P698

Q36586263-FD3F1168-B987-4179-8EA9-B83033DF0E64

P921

Q36586263-5EF439E2-4EFB-483A-B718-6457CD3757D7

P932

Q36586263-9CA20B3F-D18D-4041-AB58-9BD4CA009812

P356

P1433

Canadian Medical Association Journal

P1476

Rates of hemorrhage during warfarin therapy for atrial fibrillation.

@en

P2093

Anne M Holbrook

http://www.w3.org/2001/XMLSchema#string

Chelsea Hellings

http://www.w3.org/2001/XMLSchema#string

David N Juurlink

http://www.w3.org/2001/XMLSchema#string

J Michael Paterson

http://www.w3.org/2001/XMLSchema#string

Muhammad M Mamdani

http://www.w3.org/2001/XMLSchema#string

Tara Gomes

http://www.w3.org/2001/XMLSchema#string

P2860

A systematic review of validated methods for identifying atrial fibrillation using administrative data

Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study

Dabigatran versus warfarin in patients with atrial fibrillation

2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation

Validation of Clinical Classification Schemes for Predicting Stroke

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

Apixaban versus warfarin in patients with atrial fibrillation

Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm.

Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.

P304

E121-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1503/CMAJ.121218

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

185

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233775024

http://www.w3.org/2001/XMLSchema#string

P698

23184840

http://www.w3.org/2001/XMLSchema#string

P921

atrial fibrillation

P932

3563912

http://www.w3.org/2001/XMLSchema#string